Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
JUNSHI BIO (01877.HK) Toripalimab Injection Approved in Mainland for 13th Indication
Recommend 3 Positive 1 Negative 1 |
||||
|
||||
|
JUNSHI BIO (01877.HK) announced that it has received a Drug Registration Certificate issued by the National Medical Products Administration. Toripalimab (trade name: Tuoyi) in combination with Disitamab Vedotin, an antibody-drug conjugate independently developed by RemeGen, has been approved for a new indication for the treatment of patients with locally advanced or metastatic urothelial carcinoma with HER2 expression (defined as HER2 immunohistochemistry results of 1+, 2+ or 3+). This marks the 13th approved indication for Toripalimab injection in Mainland China. (ha/da) Auto-translated by AI This article was automatically translated by AI, the original language version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation. More Details
AASTOCKS Financial News |
||||
Copied to Clipboard
 |
||||
